Philips Continues to Demonstrate Strong Commitment to its ESG Ambitions

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has made strong progress towards realizing its key Environmental, Social, and Governance (ESG) ambitions. In 2022, Philips reached 1.81 billion people with its products and services, while further reducing operational emissions, and indirect (scope 3) emissions across the end-to-end healthcare value chain, together with its suppliers.

“We continue to move closer to our aim of improving 2 billion lives per year by 2025, while stepping up our sustainability efforts in our operations and value chain,” said Marnix van Ginneken, Chief ESG & Legal Officer at Royal Philips. “The growing momentum across the healthcare industry and among customers to reduce our collective environmental footprint encourages us on a daily basis as we continue to strive to reduce emissions across the end-to-end healthcare value chain and drive the shift to a circular economy.”

Increasing social impact

Illustrating the company’s increasing social impact, Philips’ health technology products, services and solutions improved 1.81 billion lives (1.67 billion in 2021), of which 202 million in underserved communities. This takes Philips closer to its goal of improving 2 billion lives per year by 2025, with 300 million in underserved communities. In 2022, improved access to care in underserved communities was driven by shared-value partnerships, the development of innovative digital solutions, and the roll-out of new business and financing models that are both sustainable and scalable.

Other key developments within the social dimension include a 30% representation of women in senior leadership roles, increased focus on employee health and well-being (both physical and mental health), and continued emphasis on ensuring a safe and healthy workplace.

Creating sustainable innovations

In 2022, the contribution from circular revenues increased to 18% of sales (2021: 16%). In 2022, Philips saw 10% more returns of large medical equipment compared to 2021 and closed the loop on more than 3,500 systems. Additionally, consumers started to make use of the newly introduced options to rent a Philips Avent breast pump or IPL Lumea hair removal device.

EcoDesigned products and solutions increased their revenue contribution to 71.7% (2021: 70.5%), supported by grooming and beauty products that contain over 25% recycled plastics and Oral Healthcare introducing its first brush heads containing 75% bio-based materials. Demand for sustainable healthcare systems is supported by the MR 5300 with its industry-leading BlueSeal magnet, helping radiology departments massively reduce the need for scarce helium gas.

Reducing operational emissions and waste

In addition to remaining carbon-neutral in its operations (since 2020), Philips achieved 77% (2021: 74%) renewable energy usage, exceeding the 75% goal for 2025. It also reduced transport- and distribution-related CO₂ emissions by 22% through a stricter air-freight policy and optimized warehouse locations.

Philips improved the circularity of its waste stream to 91% (2021: 87%), increasingly recycling, re-using or reducing waste. An example is the replacement of single use plastic in supplier packaging with boxes that can be used repeatedly. As a result, less than 0.1% of the remaining operational waste was land-filled, in line with our zero-waste to landfill ambition.

Philips is also proud that CDP, a global NGO that assesses the CO₂ emissions performance and management of reporting companies, ranked Philips on the CDP Climate Change ’A’ List for the 10th time in a row, thanks to the company’s continued climate performance and transparency.

Advancing towards low-carbon operations and value chain

In 2022, Philips became the first health technology company with approval from the Science Based Targets initiative (SBTi) for its entire value-chain CO₂ emissions reduction targets, including Scope 1-3. In addition, 41% of suppliers (based on spend) have now committed to science-based targets (2021: 28%) – Philips’ goal is 50% by 2025.

Progressing in governance

Philips’ commitment to responsible and transparent governance is illustrated by the publication of the Philips Human Rights Report 2022, in which Philips updated stakeholders on its progress in addressing key human rights over the past year, along with plans for continuous improvement.

Philips continues to take an active role – in collaboration with global institutions such as the International Financial Reporting Standards (IFRS) Foundation, the World Economic Forum (WEF) and the European Union – to help drive the evolution towards a standard global ESG reporting framework.

For a full overview of Philips’ Environmental, Social, and Governance achievements, read chapter 5 of the Philips Annual Report 2022, which was published earlier today.

Hot this week

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.